Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Ben F M Wijnen, Frederick W Thielen, Steef Konings, Talitha Feenstra, Mark Van Der Gaag, Wim Veling, Lieuwe De Haan, Helga Ising, Mickaël Hiligsmann, Silvia M A A Evers, Filip Smit, Joran Lokkerbol

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)269-279
Number of pages11
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume20
Issue number3
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Budgets
  • Cognitive Behavioral Therapy/economics
  • Cohort Studies
  • Computer Simulation
  • Cost-Benefit Analysis
  • Health Care Costs/statistics & numerical data
  • Humans
  • Markov Chains
  • Models, Economic
  • Netherlands
  • Psychotic Disorders/economics
  • Quality-Adjusted Life Years
  • Risk
  • COST-EFFECTIVENESS ANALYSIS
  • EARLY INTERVENTION
  • ULTRA-HIGH-RISK
  • Schizophrenia
  • FOLLOW-UP
  • RISPERIDONE
  • psychosis
  • health economic modelling
  • ANTIPSYCHOTICS
  • 1ST-EPISODE PSYCHOSIS
  • 1ST EPISODE
  • cost-effectiveness
  • SCHIZOPHRENIA
  • budget impact
  • UNTREATED PSYCHOSIS
  • economic evaluation

Cite this